Ilsung Pharmaceuticals Co., Ltd. (003120.KS)
KRW 15970.0
(-0.19%)
KRW 15970.0
(-0.19%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -159.84 Billion KRW | 41.37% |
| 2022 | -272.64 Billion KRW | -438.15% |
| 2021 | -50.66 Billion KRW | -41.6% |
| 2020 | -35.77 Billion KRW | 3.7% |
| 2019 | -37.15 Billion KRW | -2569.07% |
| 2018 | -1.39 Billion KRW | 95.29% |
| 2017 | -29.52 Billion KRW | -48.55% |
| 2016 | -19.87 Billion KRW | -165.45% |
| 2015 | -7.48 Billion KRW | -23.29% |
| 2014 | -6.07 Billion KRW | 14.6% |
| 2013 | -7.11 Billion KRW | -52.92% |
| 2012 | -4.64 Billion KRW | -342.05% |
| 2011 | -1.05 Billion KRW | -1.09% |
| 2010 | -1.04 Billion KRW | 70.98% |
| 2009 | -3.58 Billion KRW | 28.39% |
| 2008 | -5 Billion KRW | 10.72% |
| 2007 | -5.6 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -121.76 Billion KRW | 6.89% |
| 2024 Q1 | -130.76 Billion KRW | 18.19% |
| 2023 Q4 | -159.84 Billion KRW | 27.75% |
| 2023 Q1 | -280.36 Billion KRW | -2.83% |
| 2023 FY | -159.84 Billion KRW | 41.37% |
| 2023 Q3 | -221.23 Billion KRW | 0.87% |
| 2023 Q2 | -223.18 Billion KRW | 20.39% |
| 2022 Q2 | -355.02 Billion KRW | -686.51% |
| 2022 Q1 | -45.13 Billion KRW | 10.9% |
| 2022 FY | -272.64 Billion KRW | -438.15% |
| 2022 Q4 | -272.64 Billion KRW | 21.57% |
| 2022 Q3 | -347.64 Billion KRW | 2.08% |
| 2021 Q2 | -53.23 Billion KRW | -9.98% |
| 2021 FY | -50.66 Billion KRW | -41.6% |
| 2021 Q4 | -50.66 Billion KRW | -0.59% |
| 2021 Q1 | -48.4 Billion KRW | -35.28% |
| 2021 Q3 | -50.36 Billion KRW | 5.39% |
| 2020 Q2 | -40.19 Billion KRW | -0.64% |
| 2020 Q1 | -39.94 Billion KRW | -7.51% |
| 2020 Q3 | -23.97 Billion KRW | 40.36% |
| 2020 FY | -35.77 Billion KRW | 3.7% |
| 2020 Q4 | -35.77 Billion KRW | -49.23% |
| 2019 Q2 | -987.37 Million KRW | 20.69% |
| 2019 Q4 | -37.15 Billion KRW | -6344.48% |
| 2019 FY | -37.15 Billion KRW | -2569.07% |
| 2019 Q1 | -1.24 Billion KRW | 10.55% |
| 2019 Q3 | -576.48 Million KRW | 41.61% |
| 2018 FY | -1.39 Billion KRW | 95.29% |
| 2018 Q2 | -31.09 Billion KRW | 0.91% |
| 2018 Q4 | -1.39 Billion KRW | 94.74% |
| 2018 Q1 | -31.38 Billion KRW | -6.31% |
| 2018 Q3 | -26.45 Billion KRW | 14.93% |
| 2017 Q3 | -34.75 Billion KRW | -2.76% |
| 2017 Q1 | -25.49 Billion KRW | -28.3% |
| 2017 FY | -29.52 Billion KRW | -48.55% |
| 2017 Q4 | -29.52 Billion KRW | 15.07% |
| 2017 Q2 | -33.82 Billion KRW | -32.66% |
| 2016 Q3 | -30.32 Billion KRW | -19.09% |
| 2016 FY | -19.87 Billion KRW | -165.45% |
| 2016 Q4 | -19.87 Billion KRW | 34.48% |
| 2016 Q2 | -25.46 Billion KRW | 36.21% |
| 2016 Q1 | -39.92 Billion KRW | -433.32% |
| 2015 Q2 | -55.26 Billion KRW | -344.26% |
| 2015 Q3 | -10.31 Billion KRW | 81.33% |
| 2015 Q4 | -7.48 Billion KRW | 27.43% |
| 2015 FY | -7.48 Billion KRW | -23.29% |
| 2015 Q1 | -12.43 Billion KRW | -104.84% |
| 2014 Q3 | -8.8 Billion KRW | 66.38% |
| 2014 Q2 | -26.17 Billion KRW | -202.02% |
| 2014 FY | -6.07 Billion KRW | 14.6% |
| 2014 Q4 | -6.07 Billion KRW | 31.0% |
| 2014 Q1 | -8.66 Billion KRW | -21.89% |
| 2013 Q3 | -12.99 Billion KRW | 71.83% |
| 2013 Q4 | -7.11 Billion KRW | 45.26% |
| 2013 FY | -7.11 Billion KRW | -52.92% |
| 2013 Q1 | -11.45 Billion KRW | -146.46% |
| 2013 Q2 | -46.11 Billion KRW | -302.41% |
| 2012 Q4 | -4.64 Billion KRW | -54.55% |
| 2012 Q3 | -3 Billion KRW | 39.68% |
| 2012 Q2 | -4.98 Billion KRW | 47.52% |
| 2012 FY | -4.64 Billion KRW | -342.05% |
| 2012 Q1 | -9.5 Billion KRW | -803.51% |
| 2011 Q3 | -3.15 Billion KRW | 62.96% |
| 2011 Q1 | -4.69 Billion KRW | -351.63% |
| 2011 Q2 | -8.52 Billion KRW | -81.39% |
| 2011 FY | -1.05 Billion KRW | -1.09% |
| 2011 Q4 | -1.05 Billion KRW | 66.69% |
| 2010 Q2 | -12.81 Billion KRW | -205.38% |
| 2010 Q1 | -4.19 Billion KRW | -17.09% |
| 2010 Q4 | -1.04 Billion KRW | 84.65% |
| 2010 Q3 | -6.77 Billion KRW | 47.11% |
| 2010 FY | -1.04 Billion KRW | 70.98% |
| 2009 Q4 | -3.58 Billion KRW | 51.5% |
| 2009 Q3 | -7.39 Billion KRW | -496.62% |
| 2009 Q2 | -1.23 Billion KRW | 2.07% |
| 2009 Q1 | -1.26 Billion KRW | 74.73% |
| 2009 FY | -3.58 Billion KRW | 28.39% |
| 2008 Q1 | 9.1 Billion KRW | 262.44% |
| 2008 Q2 | 4.61 Billion KRW | -49.37% |
| 2008 FY | -5 Billion KRW | 10.72% |
| 2008 Q3 | -3.64 Billion KRW | -178.96% |
| 2008 Q4 | -5 Billion KRW | -37.47% |
| 2007 Q2 | -10.61 Billion KRW | 40.27% |
| 2007 Q3 | -8.88 Billion KRW | 16.3% |
| 2007 FY | -5.6 Billion KRW | 0.0% |
| 2007 Q4 | -5.6 Billion KRW | 36.88% |
| 2007 Q1 | -17.77 Billion KRW | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 1915.981% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 127.944% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 151.419% |
| HANDOK Inc. | 283.45 Billion KRW | 156.392% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | 896.362% |
| Yuhan Corporation | -69.18 Billion KRW | -131.038% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 182.416% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | -4236.823% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 130.865% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | -392.87% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 311.229% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | 533.927% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | 293.707% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | 736.629% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 1915.981% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 179.547% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 193.509% |
| JW Holdings Corporation | 480.68 Billion KRW | 133.254% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 197.123% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | 136103.821% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 203.547% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 6898.196% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | 794.945% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 191.356% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | 407.549% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | 1915.981% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 200.979% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 144.628% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 203.547% |
| Yuhan Corporation | -69.18 Billion KRW | -131.038% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 217.542% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | 367.867% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 137.248% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 203.547% |
| Samjin Pharmaceuticals Co., Ltd. | 116.23 Billion KRW | 237.519% |
| Korea United Pharm Inc. | 16.42 Billion KRW | 1073.189% |
| CKD Bio Corp. | 143.29 Billion KRW | 211.55% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | 237.72% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | -564.322% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | -257.328% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | 6898.196% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 137.803% |
| Boryung Corporation | 187.72 Billion KRW | 185.148% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | -122.504% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | 311.229% |
| JW Lifescience Corporation | 26.09 Billion KRW | 712.66% |